Cyclerion Therapeutics (CYCN) Competitors $2.75 +0.07 (+2.61%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.60 -0.15 (-5.27%) As of 04/17/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. SRZN, LVTX, MRNS, FGEN, INKT, AKTX, CVKD, ALLK, ATHE, and OSTXShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Surrozen (SRZN), LAVA Therapeutics (LVTX), Marinus Pharmaceuticals (MRNS), FibroGen (FGEN), MiNK Therapeutics (INKT), Akari Therapeutics (AKTX), Cadrenal Therapeutics (CVKD), Allakos (ALLK), Alterity Therapeutics (ATHE), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Surrozen LAVA Therapeutics Marinus Pharmaceuticals FibroGen MiNK Therapeutics Akari Therapeutics Cadrenal Therapeutics Allakos Alterity Therapeutics OS Therapies Surrozen (NASDAQ:SRZN) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation. Do institutionals & insiders have more ownership in SRZN or CYCN? 66.6% of Surrozen shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 43.5% of Surrozen shares are held by company insiders. Comparatively, 36.1% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, SRZN or CYCN? Surrozen has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Do analysts recommend SRZN or CYCN? Surrozen currently has a consensus price target of $38.50, suggesting a potential upside of 294.87%. Given Surrozen's stronger consensus rating and higher possible upside, research analysts clearly believe Surrozen is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is SRZN or CYCN more profitable? Cyclerion Therapeutics' return on equity of -55.32% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets SurrozenN/A -120.51% -54.68% Cyclerion Therapeutics N/A -55.32%-48.35% Does the MarketBeat Community prefer SRZN or CYCN? Cyclerion Therapeutics received 28 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 58.62% of users gave Cyclerion Therapeutics an outperform vote while only 28.57% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformSurrozenOutperform Votes628.57% Underperform Votes1571.43% Cyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Which has stronger valuation & earnings, SRZN or CYCN? Cyclerion Therapeutics has lower revenue, but higher earnings than Surrozen. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10.66M3.00-$43.04M-$21.77-0.45Cyclerion Therapeutics$2M3.73-$5.26M-$1.22-2.25 Does the media refer more to SRZN or CYCN? In the previous week, Surrozen and Surrozen both had 1 articles in the media. Surrozen's average media sentiment score of 1.00 equaled Cyclerion Therapeutics'average media sentiment score. Company Overall Sentiment Surrozen Positive Cyclerion Therapeutics Positive SummaryCyclerion Therapeutics beats Surrozen on 9 of the 15 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.45M$6.44B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-2.256.8921.8617.80Price / Sales3.73230.57380.5497.75Price / CashN/A65.6738.2634.64Price / Book0.605.936.453.98Net Income-$5.26M$142.99M$3.22B$247.81M7 Day Performance7.42%4.43%2.85%1.80%1 Month Performance6.59%-12.72%-8.67%-6.81%1 Year Performance-14.55%-9.42%11.46%1.31% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics2.3953 of 5 stars$2.75+2.6%N/A-15.4%$7.45M$2M-2.2530Short Interest ↓Gap UpSRZNSurrozen3.6077 of 5 stars$9.49+5.4%$38.50+305.7%+4.2%$30.84M$10.66M-0.4480Short Interest ↓Positive NewsGap UpLVTXLAVA Therapeutics2.3908 of 5 stars$1.16+6.4%$3.17+173.0%-55.4%$30.51M$11.98M-1.1360Short Interest ↓MRNSMarinus Pharmaceuticals2.1411 of 5 stars$0.55-0.2%$4.79+771.6%-61.9%$30.32M$30.99M-0.22110News CoverageFGENFibroGen4.1351 of 5 stars$0.30+8.2%$10.00+3,234.4%-77.5%$30.27M$29.62M-0.24570Analyst ForecastGap DownINKTMiNK Therapeutics3.0929 of 5 stars$7.56-9.1%$37.50+396.0%-16.6%$29.98MN/A-1.9430Short Interest ↓Positive NewsAKTXAkari TherapeuticsN/A$1.11+4.0%N/A+1.2%$29.60MN/A0.009Positive NewsGap UpCVKDCadrenal Therapeutics1.9937 of 5 stars$15.45+3.0%$32.00+107.1%N/A$29.05MN/A-2.314News CoveragePositive NewsGap UpALLKAllakos4.1336 of 5 stars$0.32+0.0%$2.00+524.0%-69.2%$28.91MN/A-0.16190High Trading VolumeATHEAlterity Therapeutics2.3487 of 5 stars$3.21+2.6%$12.00+273.8%+69.1%$28.46MN/A0.0010Short Interest ↓Gap UpOSTXOS Therapies2.305 of 5 stars$1.31+4.8%$18.00+1,274.0%N/A$28.38MN/A0.00N/AGap Up Related Companies and Tools Related Companies SRZN Competitors LVTX Competitors MRNS Competitors FGEN Competitors INKT Competitors AKTX Competitors CVKD Competitors ALLK Competitors ATHE Competitors OSTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYCN Stock Free CYCN Stock Alerts